O
Osivax
A company developing "universal" vaccines able to prevent highly-mutating respiratory viral infections
About Osivax
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM™, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 volunteers tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
Read full description
For further information: www.osivax.com
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Lyon, France
- Employees
- 60
- Open positions
- None listed
- Dealroom signal
- 75.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Vaccines, Immune System, EIC, Biotech and Pharma, EIC Fund, biotech medtech and e-health, Observatoire Deeptech, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Aug 2025 | $20M | — | US Biomedical Advanced Research and Development Authority | ↗ |
| SERIES BOther financing | Mar 2025 | $11M | $44M | Meiji Seika Pharma | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Osivax is 390 monthly website visits, down 81.4% over the last three months. Osivax's team grew 5.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
European Innovation Council
Bpifrance
Bill & Melinda Gates Foundation
US National Institute of Allergy and Infectious Diseases
US Biomedical Advanced Research and Development Authority
Series A4 investors entered at this stage
Noshaq
Anaxago
EIC Fund
Meiji Seika Pharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Osivax on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Osivax’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.